TransMedics (TMDX) Q2 Revenue Jumps 38%
TransMedics Group (NASDAQ:TMDX), a leader in organ transplant technology, released its second quarter 2025 earnings on July 30, 2025. The company topped Wall Street expectations, posting GAAP revenue of $157.4 million, ahead of the $147.7 million analyst estimate, and delivering GAAP earnings per share (EPS) of $0.92—more than doubling consensus forecasts. GAAP revenue jumped 38.0% from the prior year, and management raised its full-year outlook, citing continued strong momentum in both its core Organ Care System adoption and National OCS Program logistics business. The quarter showed expanding profits, and ongoing investment in logistics and clinical programs.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
TransMedics Group provides medical devices and logistical services that help preserve donor organs for transplantation. The company’s key product is the Organ Care System (OCS), a portable perfusion platform used to keep heart, lung, and liver organs functioning outside the body. This warm perfusion technology allows for more precise preservation and assessment compared to traditional cold storage methods, enabling more successful transplants.
Source Fool.com
